GDTC
CytoMed Therapeutics Limited
Price Chart
Latest Quote
$1.00
-0.02 (-1.96%)
Current Price
| Previous Close | $1.02 |
| Open | $1.00 |
| Day High | $1.00 |
| Day Low | $0.99 |
| Volume | 9,210 |
Stock Information
Note: Financial values converted from SGD to USD
| Shares Outstanding | 11.83M |
| Total Debt | $374K |
| Cash Equivalents | $1.62M |
| Revenue | $667K |
| Net Income | $-3.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.83M |
| EPS (TTM) | $-0.26 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.52M |
| Sales | $667K |
| Income | $-3.08M |
| Book/sh | $0.43 |
| Cash/sh | $0.18 |
| Employees | 42 |
Financial Ratios
| Quick Ratio | 3.14 |
| Current Ratio | 5.17 |
| Debt/Eq | 7.04 |
Returns & Margins
| ROA | -29.31% |
| ROE | -50.28% |
| Gross Margin | 89.57% |
| Operating Margin | -535.25% |
Ownership
| Insider Ownership | 68.78% |
| Institutional Ownership | 0.18% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.67 |
| P/S | 13.75 |
| P/B | 2.33 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.01 |
| SMA50 | $1.05 |
| SMA200 | $1.33 |
| RSI | 46.88 |
| ATR | 0.0670 |
| Shares Float | 3.69M |
| Short Float | 1.08% |
| Short Ratio | 1.93 |
| Volatility | 0.02 |
| Rel Volume | 0.77 |
Performance History
| Week | -2.91% |
| Month | -9.91% |
| Quarter | -1.96% |
| 6 Months | +6.95% |
| YTD | -28.06% |
| Year | -50.50% |
| 3 Years | -75.96% |
| 10 Years | -75.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.00 | 9,210 |
| 2026-07-16 | $1.02 | 2,600 |
| 2026-07-15 | $1.02 | 700 |
| 2026-07-14 | $1.02 | 2,000 |
| 2026-07-13 | $0.96 | 23,800 |
| 2026-07-10 | $1.03 | 54,700 |
| 2026-07-09 | $0.98 | 7,100 |
| 2026-07-08 | $0.97 | 2,900 |
| 2026-07-07 | $0.97 | 1,200 |
| 2026-07-06 | $0.97 | 1,300 |
| 2026-07-02 | $0.98 | 600 |
| 2026-07-01 | $0.99 | 5,300 |
| 2026-06-30 | $1.03 | 13,200 |
| 2026-06-29 | $1.00 | 5,000 |
| 2026-06-26 | $1.02 | 57,000 |
| 2026-06-25 | $0.99 | 2,700 |
| 2026-06-24 | $0.99 | 44,500 |
| 2026-06-23 | $1.01 | 2,000 |
| 2026-06-22 | $1.08 | 2,200 |
| 2026-06-18 | $1.08 | 0 |
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $52,700 | $13,270 | $0 | $0 |
| Cost Of Revenue | $52,700 | $13,270 | $0 | $0 |
| Total Revenue | $251,432 | $53,870 | $0 | $0 |
| Operating Revenue | $251,432 | $53,870 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $16,204 | $15,745 | $39,749 | $97,023 |
| Total Expenses | $3,539,146 | $2,480,335 | $2,978,581 | $1,439,020 |
| Rent Expense Supplemental | $4,082 | $2,492 | $1,320 | $1,706 |
| Other Income Expense | $110,335 | $241,296 | $-406,235 | $-891,493 |
| Other Non Operating Income Expenses | $6,529 | - | $-76,544 | $-845,229 |
| Net Non Operating Interest Income Expense | $79,829 | $230,481 | $181,712 | $-95,397 |
| Interest Expense Non Operating | $16,204 | $15,745 | $39,749 | $97,023 |
| Operating Expense | $3,486,446 | $2,467,065 | $2,978,581 | $1,439,020 |
| Other Operating Expenses | $156,176 | $-95,425 | $665,268 | $-141,146 |
| Selling And Marketing Expense | $42,145 | $18,433 | $25,816 | $0 |
| General And Administrative Expense | $1,386,219 | $962,601 | $969,515 | $307,800 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,085,243 | $-1,950,687 | $-3,203,398 | $-2,426,993 |
| Net Interest Income | $79,829 | $230,481 | $181,712 | $-95,397 |
| Interest Income | $96,033 | $246,225 | $221,460 | $1,625 |
| Normalized Income | $-3,194,003 | $-2,181,313 | $-2,949,825 | $-2,410,175 |
| Net Income From Continuing And Discontinued Operation | $-3,085,243 | $-1,950,687 | $-3,203,398 | $-2,426,993 |
| Net Income Common Stockholders | $-3,085,243 | $-1,950,687 | $-3,203,398 | $-2,426,993 |
| Net Income | $-3,085,243 | $-1,950,687 | $-3,203,398 | $-2,426,993 |
| Net Income Including Noncontrolling Interests | $-3,097,551 | $-1,954,689 | $-3,203,610 | $-2,427,181 |
| Net Income Continuous Operations | $-3,097,551 | $-1,954,689 | $-3,203,610 | $-2,427,181 |
| Pretax Income | $-3,097,551 | $-1,954,689 | $-3,203,104 | $-2,425,910 |
| Special Income Charges | $221,467 | $0 | $0 | $217 |
| Earnings From Equity Interest | $-4,954 | $10,669 | $-24,181 | $-26,001 |
| Interest Income Non Operating | $96,033 | $246,225 | $221,460 | $1,625 |
| Operating Income | $-3,287,715 | $-2,426,465 | $-2,978,581 | $-1,439,020 |
| Depreciation Amortization Depletion Income Statement | $175,789 | $94,871 | $80,651 | $86,614 |
| Depreciation And Amortization In Income Statement | $175,789 | $94,871 | $80,651 | $86,614 |
| Amortization Of Intangibles Income Statement | $23,175 | $9,733 | $1,695 | $1,938 |
| Depreciation Income Statement | $152,614 | $85,138 | $78,956 | $84,676 |
| Gross Profit | $198,731 | $40,600 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | - | - | $-0.30 | $-0.22 |
| Basic EPS | - | - | $-0.30 | $-0.22 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-51,937 | $-3,445 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,878,840 | $-1,909,631 | $-2,562,419 | $-2,004,114 |
| Total Unusual Items | $108,760 | $230,626 | $-305,509 | $-20,263 |
| Total Unusual Items Excluding Goodwill | $108,760 | $230,626 | $-305,509 | $-20,263 |
| Reconciled Depreciation | $311,267 | $259,939 | $295,427 | $304,510 |
| EBITDA (Bullshit earnings) | $-2,770,080 | $-1,679,005 | $-2,867,929 | $-2,024,377 |
| EBIT | $-3,081,347 | $-1,938,944 | $-3,163,356 | $-2,328,887 |
| Diluted NI Availto Com Stockholders | $-3,085,243 | $-1,950,687 | $-3,203,398 | $-2,426,993 |
| Minority Interests | $12,308 | $4,002 | $212 | $188 |
| Tax Provision | $0 | $0 | $506 | $1,271 |
| Gain On Sale Of Business | $228,062 | $0 | $0 | - |
| Impairment Of Capital Assets | $6,595 | $0 | $0 | - |
| Gain On Sale Of Security | $-112,707 | $230,626 | $-305,509 | $-20,480 |
| Other Taxes | $7,342 | $6,520 | $5,163 | $5,461 |
| Amortization | $23,175 | $9,733 | $1,695 | $1,938 |
| Research And Development | $1,718,775 | $1,480,064 | $1,232,167 | $1,180,292 |
| Selling General And Administration | $1,428,364 | $981,034 | $995,332 | $307,800 |
| Other Gand A | $362,483 | $406,926 | $396,995 | $142,814 |
| Insurance And Claims | $0 | $73,144 | $219,195 | $0 |
| Rent And Landing Fees | $4,082 | $2,492 | $1,320 | $1,706 |
| Salaries And Wages | $1,019,653 | $480,039 | $352,005 | $163,280 |
| Gain On Sale Of Ppe | - | $0 | $0 | $217 |
| Diluted Average Shares | - | - | $8,239,555 | $8,479,428 |
| Basic Average Shares | - | - | $8,239,555 | $8,479,428 |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,975,780 | $6,877,434 | $8,706,438 | $440,388 |
| Total Assets | $6,189,118 | $7,803,489 | $9,587,082 | $4,051,480 |
| Total Non Current Assets | $3,349,955 | $3,152,358 | $1,761,207 | $2,118,494 |
| Non Current Accounts Receivable | $377,691 | $387,549 | - | - |
| Investmentin Financial Assets | $14,115 | $0 | - | - |
| Goodwill And Other Intangible Assets | $96,805 | $72,123 | $9,621 | $14,579 |
| Other Intangible Assets | $96,530 | $71,848 | $9,346 | $14,304 |
| Current Assets | $2,839,163 | $4,651,131 | $7,825,875 | $1,932,987 |
| Prepaid Assets | $1,112,600 | $704,663 | $695,120 | $663,919 |
| Receivables | $102,355 | $93,948 | $158,700 | $44,632 |
| Other Receivables | $16,903 | $48,926 | $10,315 | $44,632 |
| Taxes Receivable | $4,066 | $2,242 | $3,651 | - |
| Accrued Interest Receivable | $884 | $28,222 | $144,734 | - |
| Accounts Receivable | $80,501 | $14,558 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $1,624,209 | $3,852,520 | $6,972,055 | $1,224,436 |
| Cash And Cash Equivalents | $1,624,209 | $3,852,520 | $6,972,055 | $1,224,436 |
| Cash Financial | $1,624,209 | $3,852,520 | $6,972,055 | $1,224,436 |
| Debt | ||||
| Total Debt | $374,033 | $359,064 | $347,261 | $3,270,340 |
| Long Term Debt And Capital Lease Obligation | $327,182 | $323,478 | $316,063 | $368,587 |
| Long Term Debt | $285,744 | $305,629 | $316,063 | $363,387 |
| Current Debt And Capital Lease Obligation | $46,851 | $35,586 | $31,198 | $2,901,753 |
| Current Debt | $31,660 | $29,182 | $26,296 | $2,895,777 |
| Other Current Borrowings | $31,660 | $29,182 | $26,296 | $2,895,777 |
| Net Debt | - | - | - | $2,034,728 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $876,857 | $793,669 | $871,764 | $3,597,042 |
| Total Non Current Liabilities Net Minority Interest | $327,182 | $323,478 | $316,063 | $368,587 |
| Current Liabilities | $549,675 | $470,191 | $555,701 | $3,228,455 |
| Other Current Liabilities | $19,427 | $9,259 | $113,639 | - |
| Current Deferred Liabilities | $141,693 | $84,602 | $6,511 | $7,056 |
| Payables And Accrued Expenses | $341,704 | $340,745 | $404,353 | $319,646 |
| Payables | $146,086 | $58,849 | $58,168 | $136,792 |
| Other Payable | $47,341 | $28,905 | $39,087 | $123,237 |
| Total Tax Payable | $2,058 | $0 | $0 | $1,237 |
| Accounts Payable | $96,687 | $29,944 | $19,081 | $11,338 |
| Equity | ||||
| Common Stock Equity | $5,072,585 | $6,949,557 | $8,716,059 | $454,967 |
| Total Equity Gross Minority Interest | $5,312,261 | $7,009,820 | $8,715,318 | $454,438 |
| Stockholders Equity | $5,072,585 | $6,949,557 | $8,716,059 | $454,967 |
| Other Equity Interest | $86,210 | - | $57,303 | - |
| Gains Losses Not Affecting Retained Earnings | $468,860 | $15,676 | $-168,508 | $-98,813 |
| Other Equity Adjustments | $408,190 | $57,343 | - | - |
| Retained Earnings | $-14,593,998 | $-11,508,755 | $-9,558,068 | $-6,354,670 |
| Long Term Equity Investment | $0 | $171,258 | $151,201 | $185,577 |
| Other | ||||
| Ordinary Shares Number | $9,168,192 | $8,944,627 | $8,936,355 | $8,479,428 |
| Share Issued | $9,168,192 | $8,944,627 | $8,936,355 | $8,479,428 |
| Tangible Book Value | $4,975,780 | $6,877,434 | $8,706,438 | $440,388 |
| Invested Capital | $5,389,990 | $7,284,368 | $9,058,418 | $3,714,131 |
| Working Capital | $2,289,488 | $4,180,940 | $7,270,174 | $-1,295,469 |
| Capital Lease Obligations | $56,628 | $24,253 | $4,902 | $11,176 |
| Total Capitalization | $5,358,329 | $7,255,185 | $9,032,122 | $818,354 |
| Minority Interest | $239,676 | $60,263 | $-741 | $-529 |
| Foreign Currency Translation Adjustments | $60,669 | $-41,667 | $-168,508 | $-98,813 |
| Capital Stock | $19,111,513 | $18,442,635 | $18,385,332 | $6,908,449 |
| Common Stock | $19,111,513 | $18,442,635 | $18,385,332 | $6,908,449 |
| Long Term Capital Lease Obligation | $41,437 | $17,849 | $0 | $5,200 |
| Current Deferred Revenue | $141,693 | $84,602 | $6,511 | $7,056 |
| Current Capital Lease Obligation | $15,190 | $6,404 | $4,902 | $5,976 |
| Current Accrued Expenses | $195,618 | $281,895 | $346,185 | $182,853 |
| Investments And Advances | $14,115 | $171,258 | $151,201 | $185,577 |
| Available For Sale Securities | $14,115 | - | - | - |
| Investmentsin Associatesat Cost | $0 | $171,258 | $151,201 | $185,577 |
| Goodwill | $275 | $275 | $275 | $275 |
| Net PPE | $2,861,344 | $2,521,428 | $1,600,385 | $1,918,338 |
| Accumulated Depreciation | $-1,710,918 | $-1,369,501 | $-1,057,771 | $-815,964 |
| Gross PPE | $4,572,262 | $3,890,930 | $2,658,156 | $2,734,302 |
| Other Properties | $2,109,009 | $1,542,934 | $1,291,758 | $1,318,960 |
| Machinery Furniture Equipment | $397,405 | $347,092 | $255,940 | $260,435 |
| Buildings And Improvements | $1,591,786 | $1,545,115 | $821,962 | $848,831 |
| Land And Improvements | $474,062 | $455,789 | $288,496 | $306,075 |
| Properties | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | - | - | $0 | $980 |
| Duefrom Related Parties Current | - | - | - | $0 |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,410,892 | $-3,258,794 | $-2,782,206 | $-1,451,141 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,865,895 | $-2,100,460 | $-2,737,022 | $-1,083,904 |
| Cash Flow From Continuing Operating Activities | $-2,865,895 | $-2,100,460 | $-2,737,022 | $-1,083,904 |
| Operating Gains Losses | $-168,135 | $-130,286 | $195,719 | $8,998 |
| Investing Activities | ||||
| Capital Expenditure | $-544,998 | $-1,158,334 | $-45,184 | $-367,237 |
| Investing Cash Flow | $720,285 | $873,179 | $-2,116,644 | $-366,858 |
| Cash Flow From Continuing Investing Activities | $720,285 | $873,179 | $-2,116,644 | $-366,858 |
| Net Other Investing Changes | $-15,909 | $-387,549 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $219,425 | $0 | $8,764,048 | $947,673 |
| Financing Cash Flow | $161,723 | $-50,298 | $8,463,977 | $750,850 |
| Cash Flow From Continuing Financing Activities | $161,723 | $-50,298 | $8,463,977 | $750,850 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $219,425 | $0 | $8,764,048 | $947,673 |
| Common Stock Issuance | $219,425 | $0 | $8,764,048 | $947,673 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-41,499 | $-34,553 | $-263,863 | $-332,330 |
| End Cash Position | $1,624,209 | $3,640,670 | $4,824,353 | $1,224,436 |
| Beginning Cash Position | $3,640,670 | $4,824,353 | $1,224,436 | $1,947,641 |
| Effect Of Exchange Rate Changes | $-32,574 | $93,895 | $-10,395 | $-23,293 |
| Changes In Cash | $-1,983,887 | $-1,277,578 | $3,610,312 | $-699,912 |
| Interest Paid Cff | $-16,204 | $-15,745 | $-36,207 | $-97,023 |
| Net Issuance Payments Of Debt | $-41,499 | $-34,553 | $-263,863 | $-99,801 |
| Net Long Term Debt Issuance | $-41,499 | $-34,553 | $-263,863 | $-99,801 |
| Long Term Debt Payments | $-41,499 | $-34,553 | $-263,863 | $-332,330 |
| Interest Received Cfi | $125,707 | $360,860 | $76,243 | $0 |
| Net Investment Purchase And Sale | $211,850 | $1,935,853 | $-2,147,703 | $0 |
| Sale Of Investment | $211,850 | $1,935,853 | - | - |
| Net Business Purchase And Sale | $943,635 | $122,349 | $0 | $0 |
| Sale Of Business | $943,635 | $122,349 | $0 | - |
| Net Intangibles Purchase And Sale | $-50,601 | $-73,023 | $0 | $0 |
| Purchase Of Intangibles | $-50,601 | $-73,023 | $0 | $0 |
| Net PPE Purchase And Sale | $-494,396 | $-1,085,311 | $-45,184 | $-366,858 |
| Purchase Of PPE | $-494,396 | $-1,085,311 | $-45,184 | $-367,237 |
| Taxes Refund Paid | $0 | $0 | $-1,701 | $0 |
| Interest Received Cfo | $0 | $1,877 | $483 | $1,625 |
| Change In Working Capital | $-376,315 | $-46,821 | $81,322 | $85,185 |
| Change In Other Working Capital | $55,847 | $79,282 | $1,513 | $-7,742 |
| Change In Payables And Accrued Expense | $-132 | $-64,799 | $83,885 | $205,447 |
| Change In Payable | $-132 | $-64,799 | $83,885 | $205,447 |
| Change In Receivables | $-432,029 | $-61,303 | $-4,076 | $-112,520 |
| Other Non Cash Items | $-79,829 | $-230,481 | $-181,712 | $95,397 |
| Stock Based Compensation | $538,073 | $0 | $0 | - |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $76,544 | $845,229 |
| Asset Impairment Charge | $6,595 | $0 | $0 | $1,062 |
| Depreciation Amortization Depletion | $311,267 | $259,939 | $295,427 | $304,510 |
| Depreciation And Amortization | $311,267 | $259,939 | $295,427 | $304,510 |
| Amortization Cash Flow | $23,673 | $10,231 | $4,958 | $10,231 |
| Amortization Of Intangibles | $23,673 | $10,231 | $4,958 | $10,231 |
| Depreciation | $287,594 | $249,709 | $290,469 | $294,279 |
| Earnings Losses From Equity Investments | $4,954 | $-10,669 | $24,181 | $26,001 |
| Gain Loss On Investment Securities | $10,169 | $-107,190 | $173,502 | - |
| Net Foreign Currency Exchange Gain Loss | $44,805 | $-12,427 | $-1,964 | $-16,786 |
| Gain Loss On Sale Of Business | $-228,062 | $0 | $0 | - |
| Net Income From Continuing Operations | $-3,097,551 | $-1,954,689 | $-3,203,104 | $-2,425,910 |
| Issuance Of Debt | - | $0 | $0 | $232,529 |
| Long Term Debt Issuance | - | $0 | $0 | $232,529 |
| Sale Of PPE | - | $0 | $0 | $380 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $-217 |
| Net Short Term Debt Issuance | - | - | $-232,529 | $-38,755 |
| Short Term Debt Payments | - | - | $-232,529 | $-271,284 |
| Short Term Debt Issuance | - | - | $0 | $232,529 |
| Purchase Of Investment | - | - | $-2,147,703 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
Fetched: 2026-07-17